D. E. Shaw & Co., Inc. Spero Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding SPRO
# of Institutions
49Shares Held
13.9MCall Options Held
200Put Options Held
200-
Anson Funds Management LP Dallas, TX3.75MShares$3.56 Million0.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$1.68 Million0.0% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$1.29 Million14.54% of portfolio
-
Acadian Asset Management LLC Boston, MA1.07MShares$1.02 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny975KShares$925,9200.0% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $33.3M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...